Poolbeg Pharma PLC (AIM:POLB) POLB 001 data to be presented at ASH

Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

POLB 001 Reduces Cytokine Release Syndrome (CRS) in an in vivo animal model

Positive results reinforce POLB 001’s potential in the prevention and treatment of cancer immunotherapy-induced CRS

ASH is the world’s premier conference focussing on haematological malignancies

6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces that it will present a poster detailing POLB 001’s efficacy in reducing immunotherapy-induced CRS in an in vivo animal model, at the 66th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, taking place 7-10 December 2024 in San Diego, California.

Poolbeg’s poster presentation will provide insights into the results obtained from a POLB 001 in vivo study, a mouse model of immunotherapy-induced CRS. The positive results highlighted POLB 001’s potential in the prevention and treatment of cancer immunotherapy-induced CRS. CRS can occur in >70%[1] of patients treated with T cell engaging bispecific antibodies, or CAR T cell therapies. CRS of any grade can lead to prolonged hospital stays and mortality risk. The administration of these cancer immunotherapies is therefore restricted only to specialist cancer centres, which has created a “bottleneck” in providing seamless, cost-efficient access to these treatments for the patients who need them.

Mark Sumeray MD, Consultant Clinical Advisor for Poolbeg, commented: “These data underscore the potential for POLB 001 to prevent or reduce the severity of CRS. If this effect is demonstrated in the clinic, this would enable broader, safer delivery of cancer immunotherapies, including in an out-patient setting. We look forward to sharing these important findings with the global hematology community at ASH.”

Title: POLB 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

Session Name: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I

Session Date and Time: Saturday, 7 December 2024, 5:30 PM – 7:30 PM PST

Location: San Diego Convention Center, Halls G-H

Authors:  Liam Tremble, PhD, MSc, BSc, Paula Maguire, PhD, Jiwon Yang, PhD, James G Keck, Laura Maher, MSc, Mark Graham, Martin F Kaiser, MD, FRCP, FRCPath, Emma Searle, MD, PhD and Mark Sumeray, MD

Abstract Number: 2061

To schedule a meeting with the Company, please contact partnering@poolbegpharma.com.

Enquiries 

About Poolbeg Pharma plc 

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on acquiring, developing and commercialising innovative medicines that will help improve the lives of patients with rare and orphan diseases and where there is a high unmet medical need. Poolbeg comprises a strong and growing portfolio of development assets. For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.